

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bortezomib

INITIATION – plasma cell dyscrasia

Prerequisites (tick box where appropriate)

- ☐ The patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment

INITIATION – Waldenström Macroglobulinaemia

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment
and
☐ The patient has not received prior bortezomib treatment

CONTINUATION – Waldenström Macroglobulinaemia

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

- ☐ Patient has no evidence of clinical disease progression during bortezomib use

I confirm that the above details are correct:

Signed: Date: